Results 51 to 60 of about 4,121 (173)
ABSTRACT Purpose To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection. Methods This prospective
Preeti Dhanasekaran +9 more
wiley +1 more source
Objective Proadrenomedullin (pro‐ADM) is a peptide implicated in immunomodulation, with higher levels observed in inflammatory conditions, cardiovascular impairment, and sepsis. Although extensively studied in acute disorders, its potential as a biomarker in inflammatory arthritis remains underexplored.
Nefeli Stavroula Papastathopoulou +10 more
wiley +1 more source
Ankilozan Spondilit Hastalarında Yaşam Kalitesini ve Fonksiyonel Durumu Hangi Faktörler Etkiler?
Giriş: Bu çalışma, Ankilozan spondilit (AS) hastalarında fonksiyonel durumu ve yaşam kalitesini etkileyen olası faktörleri belirlemek amacıyla yapıldı.Materyal ve Metot: Çalışmaya AS'li toplam 88 adet gönüllü Türk hasta dahil edildi.
Gülcan Gürer +4 more
doaj +1 more source
ABSTRACT Objective Acute anterior uveitis (AAU) is the most common extra‐musculoskeletal manifestation of axial spondyloarthritis (axSpA). This study compared the effect of the tumor necrosis factor inhibitor (TNFi) certolizumab pegol (CZP) with standard non‐biologic care, on AAU flare rate in patients with axSpA and high risk of recurrent uveitis ...
Nigil Haroon +8 more
wiley +1 more source
Understanding the drivers of BASDAI and back pain scores in psoriatic arthritis
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is widely used to assess axial disease activity in psoriatic arthritis (PsA). However, 5 of its 6 questions reflect general disease activity rather than axial-specific symptoms. We aimed to evaluate the performance of BASDAI and its back pain subscore in assessing axial disease in PsA ...
Pankti Mehta +6 more
openaire +2 more sources
Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts [PDF]
The availability of population-specific normative data regarding disease severity measures is essential for patient assessment. The goals of the current study were to characterize the pattern of ankylosing spondylitis (AS) in Portuguese patients and to develop reference centile charts for BASDAI, BASFI, BASMI and mSASSS, the most widely used assessment
Pimentel-Santos, Fernando M. +17 more
openaire +7 more sources
Serum chitotriosidase and neopterin levels in patients with ankylosing spondylitis
Background: The aim of this study was to assess the serum chitotriosidase (ChT) and neopterin levels in patients with ankylosing spondylitis (AS) and to evaluate whether serum ChT and neopterin levels are related to disease activity.
Ferdi Yavuz +3 more
doaj +1 more source
Objective This study aims to investigate the impact of nonsteroidal anti‐inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX‐2 inhibitors [COX2i] and nonselective NSAIDs [ns‐NSAIDs]) and disease subgroups (radiographic [r‐axSpA] and nonradiographic [nr‐axSpA ...
Murat Torgutalp +8 more
wiley +1 more source
In regard to the mono‐segmental thoracic and lumbar nonfusion in patients with ankylosing spondylitis, we built a new classification system based on CT and MRI data and describe its clinical distribution characteristics and occurrence risk factors for the first time. ABSTRACT Study Design Retrospective cohort study.
Bingchuan Liu +4 more
wiley +1 more source
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis [PDF]
TNFalpha blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS).To identify parameters predicting the clinical response to TNF blockers in AS.Patients with active AS participated in two placebo controlled, randomised trials conducted in Germany with infliximab (n = 69) and etanercept (n = 30), respectively.
M, Rudwaleit +4 more
openaire +2 more sources

